NCT05578586 A Pilot Study for Optimizing Meropenem Administration in the ICU
| NCT ID | NCT05578586 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Drug Effect |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2021-12-14 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2021-12-14 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Can antibiotic drugs be administered faster and make acceptable serum concentrations if we give short but multiple infusions compared to long and fewer infusions? In this study we will compare giving meropenem 1 gram 6 times daily in 15 minutes infusions to the recommended 2 gram 3 times daily in 3 hours infusions. In patients in the intensive care unit, the need for intravenous access is of essence. If 6 short infusions results in the same serum concentrations as 3 long infusions, we will increase intravenous access from 15 to 22.5 hours daily.
Eligibility Criteria
Inclusion Criteria: 1. Patients ≥ 18 years admitted to the ICU at Oslo University Hospital, Rikshospitalet and 2. who shall be treated with meropenem because of proven or suspected serious infection and 3. who give their written informed consent either directly or through next of kin Exclusion Criteria: Patients 1. with known hypersensistivity to betalactam antibiotics or 2. who use of valproat or 3. who are pregnant or 4. the lack of consent.
Contact & Investigator
Ingvild Nordøy, PhD
PRINCIPAL INVESTIGATOR
Oslo University Hospital
Frequently Asked Questions
Who can join the NCT05578586 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Drug Effect. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05578586 currently recruiting?
Yes, NCT05578586 is actively recruiting participants. Contact the research team at inordoy@ous-hf.no for enrollment information.
Where is the NCT05578586 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT05578586 clinical trial?
NCT05578586 is sponsored by Oslo University Hospital. The principal investigator is Ingvild Nordøy, PhD at Oslo University Hospital. The trial plans to enroll 50 participants.